Appeal No. 1996-0160
Application 07/898,691
2
18 and 23 have been canceled. Claim 1 is illustrative of the subject matter on appeal and
reads as follows:
1. A method of treating tropical spastic paresis in mammals which comprise
administering an effective amount of a peptide of the formula (I):
a b
R -Ser-Thr-Thr-Thr-Asn-Tyr-R (I)
a b
where R represents an amino terminal residue Ala-, D-Ala- or Cys-Ala- and R
represents a carboxy terminal residue -Thr, -Thr-amide, -Thr-Cys or Thr-Cys-amide; or a
peptide of formula (II):
1 2 3 4 5
R -R -R -R -R (II)
1 6 6 6
where R is an amino acid terminal residue XR or R wherein R is Thr-, Ser-, Asn-, Leu-,
Ile-, Arg-, or Glu- and X is Cys,
2
R is Thr, Ser, or Asp,
3
R is Thr, Ser, Asn, Arg, Gln, Lys or Trp,
4
R is Tyr,
5 7 7 7
and R is a carboxy terminal residue which is R X or R wherein R may be any amino acid
and X is Cys or a physiologically acceptable salt thereof.
The references relied upon by the examiner are:
2The claims before us were finally amended in Paper No. 33, filed October 11,
1995. We point out that there are two typographical errors which appear to have been
overlooked by the appellants and the examiner. We direct attention to claim 3, line 2,
which should read “an” effective blocking amount; and to claim 9, line 1, which should read
“HTLV-I.” In the event of further prosecution of the application, these errors should be
corrected.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007